FDA delays LEQEMBI weekly Alzheimer's drug by three months
FDA extended review of Eisai's weekly subcutaneous lecanemab formulation to August 24, 2026, signaling continued scrutiny of anti-amyloid Alzheimer's therapies despite recent approvals.
Neomorph Closes $100M Series B With First Patient Dosed
Neomorph raised $100M in Series B funding to advance NEO-811, a molecular glue degrader with a first-in-human patient already dosed in Phase 1/2 trials for renal cancer, backed by Deerfield Management and pharma giants Novo Nordisk, Biogen, and AbbVie.